Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Bivalirudin market in this environment.
In terms of revenue, this research report indicated that the global Bivalirudin market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Bivalirudin industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The ???Bachem aims at producing XX Bivalirudin in 2020, with XX % production to take place in global market, ????Teva Pharmaceutical Industries accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Bivalirudin Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Bivalirudin Market?
Bachem
Teva Pharmaceutical Industries
Ambiopharm
PolyPeptide
Plantex
Salubris
Suzhou No.4 Pharmaceutical Factory
SOHO-YIMING Pharmaceuticals
...
Major Type of Bivalirudin Covered in XYZResearch report:
≥99.0%
<99.0%
Application Segments Covered in XYZResearch Market
Thrombin Inhibitor
Application 2
Application 3
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Bivalirudin Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 ≥99.0% -Product Introduction and Major Manufacturers
1.1.2 <99.0% -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Bivalirudin Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Bivalirudin Market
3.1.1 Top Companies leading Bivalirudin Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Bivalirudin Market
3.2.1 Top Companies leading Bivalirudin Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Bivalirudin Market
3.3.1 Top Companies leading Bivalirudin Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Bivalirudin Market
3.4.1 Top Companies leading Bivalirudin Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Bivalirudin Market
3.5.1 Top Companies leading Bivalirudin Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Bivalirudin Market
3.6.1 Top Companies leading Bivalirudin Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Bivalirudin Market
3.7.1 Top Companies leading Bivalirudin Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Bivalirudin Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Bivalirudin Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Bivalirudin Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Bivalirudin Sales and Growth Rate (2021-2026)
5.2 Global Bivalirudin Sales Value and Growth Rate (2021-2026)
6 Bivalirudin Competitive Analysis
6.1 Bachem
6.1.1 Bachem Company Profiles
6.1.2 Bachem Product Introduction
6.1.3 Bachem Bivalirudin Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Teva Pharmaceutical Industries
6.2.1 Teva Pharmaceutical Industries Company Profiles
6.2.2 Teva Pharmaceutical Industries Product Introduction
6.2.3 Teva Pharmaceutical Industries Bivalirudin Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Ambiopharm
6.3.1 Ambiopharm Company Profiles
6.3.2 Ambiopharm Product Introduction
6.3.3 Ambiopharm Bivalirudin Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 PolyPeptide
6.4.1 PolyPeptide Company Profiles
6.4.2 PolyPeptide Product Introduction
6.4.3 PolyPeptide Bivalirudin Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Plantex
6.5.1 Plantex Company Profiles
6.5.2 Plantex Product Introduction
6.5.3 Plantex Bivalirudin Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Salubris
6.6.1 Salubris Company Profiles
6.6.2 Salubris Product Introduction
6.6.3 Salubris Bivalirudin Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Suzhou No.4 Pharmaceutical Factory
6.7.1 Suzhou No.4 Pharmaceutical Factory Company Profiles
6.7.2 Suzhou No.4 Pharmaceutical Factory Product Introduction
6.7.3 Suzhou No.4 Pharmaceutical Factory Bivalirudin Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 SOHO-YIMING Pharmaceuticals
6.8.1 SOHO-YIMING Pharmaceuticals Company Profiles
6.8.2 SOHO-YIMING Pharmaceuticals Product Introduction
6.8.3 SOHO-YIMING Pharmaceuticals Bivalirudin Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
7 Conclusion